Journal of Nuclear Cardiology最新文献

{"title":"I can see clearly now the blur has gone: Deep learning efficiencies in single-photon emission computed tomography myocardial perfusion imaging","authors":"Manish Motwani MB ChB, PhD","doi":"10.1016/j.nuclcard.2024.102091","DOIUrl":"10.1016/j.nuclcard.2024.102091","url":null,"abstract":"","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102091"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac motion correction with a deep learning network for perfusion defect assessment in single-photon emission computed tomography myocardial perfusion imaging","authors":"Xirang Zhang MS ,&nbsp;Yongyi Yang PhD ,&nbsp;P. Hendrik Pretorius PhD ,&nbsp;Piotr J. Slomka PhD ,&nbsp;Michael A. King PhD","doi":"10.1016/j.nuclcard.2024.102071","DOIUrl":"10.1016/j.nuclcard.2024.102071","url":null,"abstract":"<div><h3>Background</h3><div>In myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT), ungated studies are used for evaluation of perfusion defects despite motion blur. We investigate the potential benefit of motion correction using a deep-learning (DL) network for evaluating perfusion defects.</div></div><div><h3>Methods</h3><div>We employed a DL network for cardiac motion correction in ECG-gated SPECT-MPI images, wherein the image data from different cardiac phases are combined with respect to a reference gate to reduce motion blur. For training the DL network, 197 cases were used. Given the variability of gated images during the cardiac cycle, we investigated the detectability of perfusion defects in two distinct reference gates. To assess perfusion defect detection, we performed receiver-operating characteristic (ROC) analyses on the motion-corrected images using a separate test dataset of clinical 194 subjects, in which studies were created from actual patient data with inserted simulated-lesions as ground truth. The reconstructed images were assessed by the quantitative-perfusion SPECT (QPS) software. We also evaluated the performance on reduced-count studies (by two and four folds).</div></div><div><h3>Results</h3><div>The quantitative results, measured by area-under-the-ROC curve (AUC), demonstrated that DL motion correction improves the detectability of perfusion defects significantly on both standard- and reduced-count studies, and that the detectability can vary with reference cardiac phases. A joint assessment from two reference phases achieved AUC = 0.841 on the quarter-count data, higher than with ungated full-count data (AUC = 0.795, <em>P</em>-value = 0.0054).</div></div><div><h3>Conclusions</h3><div>DL motion correction can benefit assessment of perfusion defects in standard- and reduced-count SPECT-MPI studies. It can also be beneficial to evaluate perfusion images over multiple cardiac phases.</div></div>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102071"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the effect of repeat positron emission tomography imaging on treatment response and cardiovascular outcomes among a homogenously treated cohort of patients with suspected cardiac sarcoidosis","authors":"Chaitanya Rojulpote MD ,&nbsp;Abhijit Bhattaru BA ,&nbsp;Shivaraj Patil MD ,&nbsp;Sarah L. Adams DO ,&nbsp;Jonathan A. Salas BS ,&nbsp;Mahesh K. Vidula MD ,&nbsp;Raul Porto Perez MD ,&nbsp;Wumesh Kc MD, PhD ,&nbsp;Karen Patterson MD ,&nbsp;Caitlin B. Clancy MD ,&nbsp;Milton Rossman MD ,&nbsp;Lee Goldberg MD ,&nbsp;Paco E. Bravo MD","doi":"10.1016/j.nuclcard.2024.102082","DOIUrl":"10.1016/j.nuclcard.2024.102082","url":null,"abstract":"<div><h3>Background</h3><div>Serial positron emission tomography (PET) imaging is routinely used to monitor treatment response in patients with suspected cardiac sarcoidosis (CS). Corticosteroids remain the mainstay of therapy in CS. However, there are no data available on the cardiovascular outcomes and optimal timing interval to obtain repeat PET while factoring in the influence of corticosteroid taper in relation to surveillance imaging.</div></div><div><h3>Methods</h3><div>We identified 81 patients with suspected CS (age: 56.3 ± 1.9, 67% male, left ventricle ejection fraction: 46.5 ± 3) who were not on immunosuppression treatment and demonstrated inflammation on baseline PET, subsequently started on moderate-dose prednisone monotherapy (i.e., 30-40 mg/day), and had a diagnostic follow-up PET. Treatment response was graded as complete treatment response (CTR) or partial treatment response (PTR) vs no response. Patients were divided into tertiles based on follow-up time between PET scans; tertile-1 (&lt;3.2 months; median: 3.1 months), tertile-2 (3.2-6.8 months; median: 5.9 months), and tertile-3 (&gt;6.8 months; median: 9.8 months). Corticosteroid taper was captured by measuring weekly changes in prednisone from the start of treatment to up to one-year follow-up. Major adverse cardiovascular events (MACEs), defined as sustained ventricular arrhythmias, were documented during the first year post baseline PET.</div></div><div><h3>Results</h3><div>Treatment response CTR/PTR rates were similar across tertiles: (tertile-1 [92%] vs tertile-2 [86.2%] vs tertile-3 [85.2%]; <em>P</em> = .76). Taper rates and one-year cumulative prednisone dose were similar between the three groups (<em>P</em> = .9). No significant difference was found in short-term MACEs between the tertile groups (<em>P</em> = .89). Similarly, MACEs did not differ significantly according to treatment response status (<em>P</em> = .39).</div></div><div><h3>Conclusions</h3><div>Surveillance time and taper rates do not seem to influence treatment response on PET scans among patients initiated on moderate-dose prednisone only. Similar MACE rates were observed despite variations in follow-up time and treatment response status.</div></div>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102082"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding best practices in nuclear cardiology: A blueprint for growth","authors":"Marcelo F. Di Carli MD, MASNC","doi":"10.1016/j.nuclcard.2025.102127","DOIUrl":"10.1016/j.nuclcard.2025.102127","url":null,"abstract":"","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102127"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rubidium-82 dose effects on myocardial blood flow measurements using a digital positron emission tomography - computed tomography scanner","authors":"David Gao MD ,&nbsp;Mehmet Aykaç PhD ,&nbsp;Charles Hayden PhD ,&nbsp;Rob S.B. Beanlands MD ,&nbsp;Robert A. deKemp PhD","doi":"10.1016/j.nuclcard.2024.102073","DOIUrl":"10.1016/j.nuclcard.2024.102073","url":null,"abstract":"","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102073"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Charting a responsible path to innovation: Embracing the next chapter in nuclear cardiology – The greatest adventures still lie ahead","authors":"Panithaya Chareonthaitawee MD","doi":"10.1016/j.nuclcard.2024.102107","DOIUrl":"10.1016/j.nuclcard.2024.102107","url":null,"abstract":"","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102107"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143105325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic utility of heart rate and blood pressure response to regadenoson stress","authors":"Andrea Torres MD ,&nbsp;Alex Yerkan BS ,&nbsp;Ayesha Abbasi MD ,&nbsp;Rami Doukky MD, MSc, MBA, FASNC","doi":"10.1016/j.nuclcard.2024.102050","DOIUrl":"10.1016/j.nuclcard.2024.102050","url":null,"abstract":"<div><h3>Background</h3><div>Although heart rate response (HRR) to regadenoson stress has been shown to be a strong predictor of outcome, it has not been investigated in a large all-comers cohort. The prognostic utility of systolic blood pressure response (SBPR) has not been investigated in comparison with HRR.</div></div><div><h3>Methods and results</h3><div>In a retrospective cohort of 10,227 patients undergoing regadenoson stress single-photon emission computed tomography myocardial perfusion imaging (MPI), HRR, and SBPR were calculated as 100×(peak hyperemia value–baseline value)/baseline value. During 35<!--> <!-->±<!--> <!-->21 months follow-up, 921 (8.8%) deaths were observed. The median HRR was 35% (interquartile range [IQR], 21% to 51%). The median SBPR was −9% (IQR, −17% to −2%). HRR and SBPR were independently associated with all-cause mortality with adjusted hazard ratio [HR] of .980 per 1% increment in HRR (CI, .977-.984) and .994 per 1% increment in SBPR (CI, .988-.999). Mortality rates increased with decreasing HRR quartile and SBPR tertile. HRR provided incremental prognostic value for all-cause mortality beyond clinical and imaging parameters (area under the curve [AUC] increase, .03; <em>P</em> <!-->&lt;<!--> <!-->.001) and SBPR data (AUC increase, .11; <em>P</em> <!-->&lt;<!--> <!-->0001). SBPR did not provide significant incremental prognostic value beyond clinical and imaging parameters or HRR data. We derived and validated HRR of &lt;20% as a cut-off that can improve risk stratification beyond clinical and MPI findings.</div></div><div><h3>Conclusion</h3><div>Among patients undergoing stress MPI, impaired HRR to regadenoson provided independent and incremental prognostic value for all-cause mortality beyond clinical, imaging, and SBPR data. SBPR positively correlates with HRR, but it does not provide incremental prognostic utility. HRR, but not SBPR, should be routinely reported and considered in assessing patients' overall risk. An abnormal HRR threshold of &lt;20% can improve risk stratification.</div></div>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102050"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142377973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The time is now: Identifying optimal imaging strategies to monitor cardiac sarcoidosis activity","authors":"Nisha A. Gilotra MD, FACC, FHFSA ,&nbsp;Sanjay Divakaran MD, MPH, FASNC","doi":"10.1016/j.nuclcard.2024.102081","DOIUrl":"10.1016/j.nuclcard.2024.102081","url":null,"abstract":"","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"43 ","pages":"Article 102081"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis","authors":"Carlos Godoy-Rivas MD ,&nbsp;Mohammed Elsadany MD ,&nbsp;Abhishek Jaiswal MD,&nbsp;Adaya Weissler-Snir MD,&nbsp;Sabeena Arora MD,&nbsp;W. Lane Duvall MD","doi":"10.1016/j.nuclcard.2024.102056","DOIUrl":"10.1016/j.nuclcard.2024.102056","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac imaging with bone-avid tracers for the diagnosis of transthyretin amyloid (ATTR) cardiac amyloidosis uses only limited quantification, but single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition can provide volumetric assessment with quantification of tracer uptake. Tafamidis is routinely used in the treatment of cardiac amyloidosis, but there are scant data on changes in imaging results during therapy. The purpose of this study was to perform a longitudinal assessment of Tc-99m-pyrophosphate (PYP) imaging to determine if tafamidis therapy results in any change in quantitative measures of tracer uptake.</div></div><div><h3>Methods</h3><div>The study incorporated a prospective, single-center study of ATTR patients being treated with tafamidis using Tc-99m-PYP SPECT/CT to quantify cardiac tracer uptake in the whole heart and left ventricle. Standardized uptake values (SUVs) were adjusted for blood pool activity. Comparison of baseline activity was made to values obtained approximately every 6 months during treatment.</div></div><div><h3>Results</h3><div>Twenty-two patients (77.0<!--> <!-->±<!--> <!-->7.5 years old, 86.4% male) were on tafamidis for 15.3<!--> <!-->±<!--> <!-->4.0 months, with an average time between baseline and final follow-up study of 16.8<!--> <!-->±<!--> <!-->4.7 months. Thirteen patients (59.1%) had multiple follow-up amyloid studies. Statistically significant reductions in total SUVs, SUV volume, and percentage of injected dose were seen. Adjusted for the maximal aortic SUV, the total SUV in the left ventricle decreased by 36.9%, the SUV volume by 38.7%, and the percentage of injected dose decreased by 34.9% (all <em>P</em> values<!--> <!-->≤<!--> <!-->0.0001). Over the study duration, there was a decrease of 7.7%/month in the measured metrics.</div></div><div><h3>Conclusion</h3><div>The quantitative SUV measurements from Tc-99m-PYP SPECT/CT revealed an overall decrease in scintographic amyloid burden during the course of tafamidis therapy, but additional work is needed to determine the optimal metrics and improve the reproducibility of the quantification.</div></div>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"42 ","pages":"Article 102056"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What do changes in myocardial bone-avid radiotracer uptake mean in transthyretin cardiac amyloidosis?","authors":"Olivier F. Clerc MD, MPH ,&nbsp;Sarah A.M. Cuddy MD, MPH ,&nbsp;Sharmila Dorbala MD, MPH","doi":"10.1016/j.nuclcard.2024.102077","DOIUrl":"10.1016/j.nuclcard.2024.102077","url":null,"abstract":"","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":"42 ","pages":"Article 102077"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}